In the preliminary findings of a study conducted with the National Taiwan University Hospital, over 50% of sample cases were reclassified as HER2-expressing when 3D pathology was applied. HSINCHU, April 16, 2025 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup at the forefront...
Read More Details
Finally We wish PressBee provided you with enough information of ( Greater Precision of HER2-Expressing Breast Cancer Treatment with 3D Pathology: New JelloX Research Collaboration )
Also on site :
- French leftists cry foul as Israel nixes visit
- Meeting with the Exporters and Investors Club
- Senior leaders are feeling the burden of cuts to middle management